End of Legacy with Beginning of New Era in U.S.: New Biosimilars to replace Humira in 2025

“For too long, foreign nations have been able to free ride off of the American people, and American patients forced to pay for too much for prescription drugs”. Donald Trump's focus on lowering prices of pharmaceuticals led to the emergence of biosimilars in U.S. insurance plans,

2025 represents a inflation point in the disease management and treatment of autoimmune diseases. Over 20 years, Humira was the prominent product in the biologics market to treat various autoimmune conditions such as rheumatoid arthritis, Crohn’s disease, plaque psoriasis and other conditions. However, in 2025, the U.S.’s biologics landscape is witnessing the shift towards the emergence of FDA-approved biosimilars and the end of Humira’s era. This shift signals the regulatory evolution, market players strategy and healthcare system’s movement toward affordable and accessible treatments for U.S. population. 

In May 2025, President Donald J. Trump signed an exclusive agreement on reducing the drug prices for Americans. Trump said “In case after case, our citizens pay massively higher prices than other nations pay for the same exact pill, from the same factory, effectively subsidizing socialism aboard with skyrocketing prices at home. So we would spend tremendous amounts of money in order to provide inexpensive drugs to another country. And when I say the price is different, you can see some examples where the price is beyond anything four times, five times different.”

AbbVie’s Humira held a significant monopoly for more than a decade in the U.S. biologics market, with generating over USD 200 billion from its launch in December 2002. However, this price came at a high cost for payers, providers, and patients. However, the launch of various biosimilars has allowed various healthcare providers to substitute Humira.

Recently Approved Humira Biosimilars in U.S.

Thus, the transition from Humira to biosimilars is driven by U.S. payers and pharmacy benefit managers, these providers have started substituting Humira. For instance, Horizon Blue Cross Blue Shield of New Jersey, has announced that from July 2025, Humira and Sterala will be replaced by their biosimilars. Additionally, South Carolina’s BlueCross BlueShield and BlueChoice HealthPlan have also reinforced the coverage of biosimilars from January 2025. This change aims at a strategic shift to improve cost-efficiency in Americas' healthcare. 

Use Cases Analysis: 

Navitus Health Solutions switched to biosimilars in 2024, leading to over USD 315 million savings and about 60% reduction in per-prescription costs. This highlights the affordability biosimilars bring to the healthcare system. Further, Debra Patt, MD, PhD, MBA, a medical oncologist at TexasOncology said that, “As chronic diseases continue to drive 90% of the nation’s $4.5 trillion in annual health care spending, expanding access to lower-cost biosimilars emerged as a critical solution.” Thus, integration of biosimilars in the U.S. insurance plans will significantly lower the cost and presents opportunities for manufacturers in the coming years.